Results 141 to 150 of about 668,253 (275)

Selenium‐Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers

open access: yesAdvanced Science, EarlyView.
This reivew summarizes Selenium as a multifunctional anticancer regulator in gynecological cancers. It reduces tumor risk, enhances therapeutic efficacy, and reduces treatment toxicity. Selenium also overcomes chemoraditherapy resistance, improving overall treatment outcomes. ABSTRACT Gynecological cancers present significant therapeutic challenges due
Hejing Liu   +9 more
wiley   +1 more source

TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk

open access: yesHepatology, EarlyView., 2022
The systematic approach in elucidating the gain‐of‐function (GOF) roles of TP53 mutations in early liver carcinogenesis. Unique downstream targets of TP53 L3 mutations were identified from chormatin immunoprecipitation sequencing in HCC cell lines, followed by a series of validation assays to substantiate the exclusive transcriptional regulations ...
Yin Kau Lam   +10 more
wiley   +1 more source

A High‐Throughput Live Imaging Platform to Investigate Circuit‐Dependent Regulation of Circadian Rhythms in Brain Tissue

open access: yesAdvanced Science, EarlyView.
Biological rhythms coordinate physiology, from genes to behavior. Study of circadian rhythms in brain tissue is constrained by limited throughput and spatial and temporal information quality. A new platform for high‐throughput, long‐term multiplexed fluorescent live imaging of circadian rhythms in brain slices is introduced.
Marco Ferrari   +3 more
wiley   +1 more source

Real‐World Treatment and Outcomes in Resectable Early‐Stage Non‐Small Cell Cancer: THASSOS‐INTL Australia Cohort

open access: yesAGING MEDICINE, EarlyView.
Australia cohort of THASSOS‐INTL; non‐interventional, multicenter, retrospective study provides insights into treatment patterns and associated survival outcomes in patients with resectable stage I‐III NSCLC in the pre‐immunotherapy era. Neoadjuvant and adjuvant therapy was reported in < 10% and < 40% patients, respectively.
Pei Ding   +4 more
wiley   +1 more source

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights

open access: yesAmerican Journal of Hematology, EarlyView.
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin   +3 more
wiley   +1 more source

Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. [PDF]

open access: yes, 2008
Mesenchymal stem cells (MSCs) from adult somatic tissues may differentiate in vitro and in vivo into multiple mesodermal tissues including bone, cartilage, adipose tissue, tendon, ligament or even muscle. MSCs preferentially home to damaged tissues where
García-Castro, J   +5 more
core  

Differentiating the Clinical and Variant Spectrum of Hardikar Syndrome From Other MED12‐Related Developmental Disorders

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The rare X‐linked female‐restricted Hardikar syndrome (HDKR, OMIM # 301068) is characterized by multiple congenital anomalies including orofacial clefts, gastrointestinal, genitourinary, and cardiac anomalies, but cognitive and neurobehavioral development is rarely impaired.
Tinne Warmoeskerken   +4 more
wiley   +1 more source

Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam   +4 more
wiley   +1 more source

Molecular characterization of the A52 murine hepatocellular carcinoma cell line

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Hepatocellular carcinoma (HCC) is a poor outcome cancer with limited therapeutic choices. To advance therapeutic development we genetically characterized the A52 murine HCC cell line. We noted genetic changes that match a subset of human HCC and this offers the opportunity to test novel targeted therapies in syngeneic mice.
Rhys Gillman   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy